Abstract
This report arises at the request of the CatSalut Exceptional Pharmacy Commission that has detected a continuous increase in demands for the reimbursement of products with an active melatonin principle in relation to different pathologies with affectation of sleep, as a result of which it requests to the AQuAS a report on the effectiveness and safety of this product or active ingredient
Keywords
Sleep disorders; Drug use; Evidence-based medicine
Bibliographic citation
Pons JMV. La melatonina exògena en els trastorns del son: eficàcia i seguretat. Barcelona: Agència de Qualitat i Avaluació Sanitàries de Catalunya; 2017.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/3504This item appears in following collections
The following license files are associated with this item: